Table 1.
Baseline characteristics of study participants.
| Abdomen (n = 355) | Upper Thigh (n = 355) | Back of Upper Arm (n = 40) | Overall (n = 750) | |
|---|---|---|---|---|
| Age (years) | 25 (21 to 30) | 25 (21 to 29) | 24 (23 to 28) | 25 (21 to 29) |
| Partner Status | ||||
| married/cohabitating | 211 (59%) | 202 (57%) | 18 (45%) | 431 (57%) |
| regular non-cohabitating partner | 144 (41%) | 153 (43%) | 22 (55%) | 319 (43%) |
| Race | ||||
| white | 104 (29%) | 104 (29%) | 20 (50%) | 228 (30%) |
| black | 28 (8%) | 29 (8%) | 1 (3%) | 58 (8%) |
| bi-/multi-racial | 223 (63%) | 222 (63%) | 19 (48%) | 464 (62%) |
| Body mass index, (kg/m2) | 27 (23 to 33) | 27 (23 to 31) | 28 (24 to 32) | 27 (23 to 32) |
| Duration of menstrual bleeding (days) | 5 (4 to 5) | 5 (4 to 6) | 5 (4 to 6) | 5 (4 to 6) |
| Any prior pregnancy | 271 (76%) | 254 (72%) | 26 (65%) | 551 (73%) |
| Vaginal sex acts per month | 12 (6 to 16) | 10 (6 to 15) | 10 (6 to 12) | 10 (6 to 15) |
| Never use condoms for STI/HIV prevention | 141 (40%) | 157 (44%) | 25 (63%) | 323 (43%) |
| Contraceptive history1 | ||||
| DMPA or NET-EN | 157 (44%) | 135 (38%) | 12 (30%) | 304 (41%) |
| Combined injectable | 43 (12%) | 66 (19%) | 4 (10%) | 113 (15%) |
| LNG-IUS | 4 (1%) | 4 (1%) | 0 (0%) | 8 (1%) |
| NuvaRing | 7 (2%) | 12 (3%) | 2 (5%) | 21 (3%) |
| Patch | 7 (2%) | 1 (<1%) | 0 (0%) | 8 (1%) |
| Pills | 220 (62%) | 218 (61%) | 31 (78%) | 469 (63%) |
| Implant | 49 (14%) | 61 (17%) | 6 (15%) | 116 (15%) |
| Condoms | 250 (70%) | 243 (68%) | 25 (63%) | 518 (69%) |
| Other | 71 (20%) | 62 (17%) | 5 (13%) | 138 (18%) |
| None | 6 (2%) | 7 (2%) | 0 (0%) | 13 (2%) |
Data are n (%) or median (IQR). DMPA=depot medroxyprogesterone acetate; NET-EN=norethisterone enanthate; LNG IUS=levonorgestrel intrauterine system.
1
Multiple responses may apply.